Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis.

Sydnor, Shelby; Chatterjee, Swarnendu; Cooney, Philip; Kaur, Simarjeet; Macmillan, Tom; Stewart, Daisy; Munro, Isobel; Bandeiras, Cátia; Paine, Abby; Felizzi, Federico

Sydnor, Shelby; Chatterjee, Swarnendu; Cooney, Philip; Kaur, Simarjeet; Macmillan, Tom; Stewart, Daisy; Munro, Isobel; Bandeiras, Cátia; Paine, Abby; Felizzi, Federico.

Afiliación

Sydnor S; Novartis Pharmaceuticals UK Ltd., London, England, UK.
Chatterjee S; CONEXTS, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Cooney P; CONEXTS, Novartis Ireland Ltd., Dublin, Ireland.
Kaur S; CONEXTS, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Macmillan T; Source Health Economics, Oxford, England, UK.
Stewart D; Source Health Economics, Oxford, England, UK.
Munro I; Source Health Economics, London, England, UK.
Bandeiras C; CONEXTS, Novartis Ireland Ltd., Dublin, Ireland.
Paine A; Source Health Economics, Oxford, England, UK.
Felizzi F; Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland. federico.felizzi@novartis.com.

Diabetes Ther ; 14(7): 1193-1216, 2023 Jul.

Article en En | MEDLINE | ID: mdl-37198521

Palabras clave

Aflibercept; Anti-VEGF; Best-corrected visual acuity; Brolucizumab; Diabetic macular oedema; Diabetic retinopathy; Network meta-analysis; Ranibizumab; Retinal thickness; Visual impairment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Systematic_reviews Idioma: En Revista: Diabetes Ther Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google